Charles River reports Q2 adjusted EPS $3.12, consensus $2.50

Reports Q2 revenue $1.03B, consensus $985.08M. James Foster, chair, president and CEO, said, “We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth. This progress was demonstrated in our solid second-quarter financial performance, driven principally by favorable results in our DSA segment.”